Completed PHASE1 INTERVENTIONAL 1-arm NCT00820508

Safety and Tolerability of CHR-2845 to Treat Haematological Diseases or Lymphoid Malignancies (CHR-2845-001)

A Phase I Study to Evaluate the Safety and Tolerability of the Histone Deacetylase Inhibitor, CHR-2845, in Patients With Advanced or Treatment Refractory Haematological Diseases or Lymphoid Malignancies

Sponsor: Chroma Therapeutics

Conditions Hematological Disease Lymphoid Malignancies

Interventions CHR-2845

Updated 5 times since 2017 Last updated: Nov 25, 2011 Started: Dec 31, 2008 Primary completion: Jul 31, 2011 Completion: Jul 31, 2011

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00820508, this PHASE1 trial focuses on Hematological Disease and Lymphoid Malignancies and remains completed. Sponsored by Chroma Therapeutics, it has been updated 5 times since 2008, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
Jan 2017 — Jun 2018 [monthly]

Completed PHASE1

First recorded

Dec 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Chroma Therapeutics

Data source: Chroma Therapeutics

For direct contact, visit the study record on ClinicalTrials.gov .

Safety and Tolerability of CHR-2845 to Treat Haematological Diseases or Lymphoid Malignancies (CHR-2845-001)

Status Flow

Change History

Eligibility Summary

Contact Information

Study Locations

Related Trials